According to the American Society of Clinical Oncology (ASCO) study, urothelial carcinoma accounts for about 90%, squamous cell carcinoma accounts for 4%, and adenocarcinoma accounts for 2% of all bladder.
Lung cancer kills nearly 1.5 to 2 million people a year worldwide and this is expected to increase further in the next ten years. Lung cancer is the most common.
China Oncology Focus, a subsidiary of Lee's Pharm, has enrolled the first patient in the double-blind Phase 3 trial of Socazolimab in combination with chemotherapy as the first-line treatment of.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ribon Therapeutics, a clinical-stage biotechnology company developing therapies targeting stress-supportive pathways, today announced its first publication in the peer-reviewed journal, cancer cell, from preclinical data on its major.
DUBLIN--(BUSINESS WIRE)--The "Liquid Biopsy for Cancer Diagnostics - Competitive Landscape and Pipeline Analysis, 2021" drug pipelines has been added to: ResearchAndMarkets.com's to offer. This report "Liquid Biopsy for Cancer Diagnostics.
Yuhan Corp. said Monday it has received sales approval for Leclaza (ingredient: Lazertinib), a drug targeting epidermal growth factor receptor (EGFR) T790M mutated non-small cell lung carcinoma (NSCLC), from the.